OncoMatch/Clinical Trials/NCT06393738
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Is NCT06393738 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including ARV-393 and Glofitamab for relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl).
Treatment: ARV-393 · Glofitamab — This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy (rituximab)
>=2 prior systemic therapies, (including rituximab)
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant (SCT)
Cannot have received: solid organ transplantation
Prior ... solid organ transplantation
Cannot have received: BCL6-targeted therapy
any prior treatment with a BCL6-targeted therapy
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate kidney function
Liver function
Adequate Liver Function
Cardiac function
Cardiac ejection fraction <45% excluded; ECG abnormalities that may affect safety or interpretation of study results excluded
Adequate bone marrow function; Adequate kidney function; Adequate Liver Function; Standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results; Cardiac ejection fraction <45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Trial Site · New Haven, Connecticut
- Clinical Trial Site · Miami, Florida
- Clinical Trial Site · Detroit, Michigan
- Clinical Trial Site · New Brunswick, New Jersey
- Clinical Trial Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06393738 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, solid organ transplantation, BCL6-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages